Adresse

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France

Standard

Tel : +33 (0)1 42 11 42 11

Urgences

Avant toute venue aux urgences, il est impératif de téléphoner au (0)1 42 11 42 11. En cas de venue sans appel préalable, vous serez transféré dans un autre hôpital.

GUSTAVE ROUSSY
1er centre de lutte contre le cancer en Europe, 3 000 professionnels mobilisés

Résistance adaptative aux thérapies anti-cancéreuses

Responsable
Pr Caroline Robert

Contact
Widad FOURAR-LAIDI, gestionnaire
Tél. : +33 (0)1.42.11.56.30
E-mail

 

Frise de présentation (bandeau): 
Résistance adaptative aux thérapies anti-cancéreuses

Publications majeures

  • Shen S et al. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nat Commun. 2019; 10(1):5713.
  • Cerezo M, Guemiri R et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma Nat Med. 2018 (12):1877-1886
  • Malka-Mahieu H et al. Molecular Pathways:  The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.  Clin Cancer Res. 2017; 23(1):21-25.
  • Boussemart L et al. Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. Cancer Res. 2016; 76(6):1476-84.
  • Boussemart L et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014; 513(7516):105-9
  • Garrido MF et al. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clin Cancer Res. 2019; 25(2):710-723.
  • Al Nakouzi N et al. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Mol Med. 2016; 8(7):761-78.
  • Faugeroux V et al. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. Eur Urol Oncol. 2019 Jan 4.
  • Massard C et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017;7(6):586-595.
Catégorie de la page: